Levoleucovorin Calcium
Phase 2Small molecule
Levoleucovorin Calcium is one of 74 small molecule programs targeting Autism Spectrum Disorder. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
73
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
160 competitors in Autism Spectrum Disorder
#DrugCompanyPhaseTrials
1Vraylar
AbbViePhase 3
Elavil
AstraZenecaPhase 3
Bumex
VValidus Pharmaceuticals
Phase 3
Rexulti
OtsukaPhase 3
Nuplazid
AACADIA Pharmaceuticals Inc.
Phase 3
Hetlioz
VVanda Pharmaceuticals
Phase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Glucophage
EMD SeronoPhase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Karxt
Bristol-Myers SquibbPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Levoleucovorin Calcium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details